Stockreport

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology [Yahoo! Finance]

Fulcrum Therapeutics, Inc.  (FULC) 
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF ? Topline data for the Phase 3 REACH clinical trial of losmapimod in FSHD expected during 4Q'24? CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeuti [Read more]